This was a Phase One, Phase Two dose escalation, dose optimization trial, and the trial confirmed the optimal induction dose of the drug followed by a maintenance dose as well. The very interesting point about this is that it’s a direct beta-catenin TCF inhibitor and there was a high response rate within the cohorts of the trial which really indicate that this drug is effective and warrants further investigation in desmoid tumors and none of the patients discontinued treatment due to adverse events...
This was a Phase One, Phase Two dose escalation, dose optimization trial, and the trial confirmed the optimal induction dose of the drug followed by a maintenance dose as well. The very interesting point about this is that it’s a direct beta-catenin TCF inhibitor and there was a high response rate within the cohorts of the trial which really indicate that this drug is effective and warrants further investigation in desmoid tumors and none of the patients discontinued treatment due to adverse events. So the drug also has a manageable and good safety profile.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.